Authorized purpose: uCT 780 produces whole-body cross-sectional CT images, including head, neck, cardiac, and vascular imaging, supports protocol-governed low-dose lung cancer screening and dual-energy material visualization, and uses DELTA deep-learning reconstruction for adult head, chest, abdomen, cardiac, and vascular applications.
Clinical role
Acquires and reconstructs CT examinations, applies DELTA at one of five noise-reduction levels, and supports dual-energy analysis by combining low- and high-energy acquisitions of the same anatomy to visualize material or chemical information and multiple-energy images.
Images and patients
CT/CTA · Multi-region
Key limitation
Keep in mind: The FDA summary states that the submitted clinical study alone cannot support promotional claims that DELTA achieves equivalent or better image quality; additional testing is needed for such claims. A radiologist and physicist should determine appropriate dose for each diagnostic task, only clinicians or dosimetrists should reduce dose, and DELTA was not thoroughly tested in pediatric patients. Low-dose lung cancer screening must follow an approved and published screening program.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: uCT 780 produces whole-body cross-sectional CT images, including head, neck, cardiac, and vascular imaging, supports protocol-governed low-dose lung cancer screening and dual-energy material visualization, and uses DELTA deep-learning reconstruction for adult head, chest, abdomen, cardiac, and vascular applications.
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Multi-region Input: CT projection data acquired on uCT 780; uWS-CT-Dual Energy Analysis accepts United Imaging CT images of the same anatomy acquired at different tube voltages and currents.
Who uses it?Intended users: A consultation with a radiologist and a physicist should be made to determine the appropriate dose to obtain diagnostic image quality for the particular clinical task; clinicians or dosimetrists should only be allowed to reduce patient dose in clinical practice.
What does the software produce?Output: Cross-sectional CT images reconstructed with FBP or DELTA and dual-energy material, chemical, and multiple-energy visualizations for qualified-user review.
What is its most important limitation?Key limitation: The FDA summary states that the submitted clinical study alone cannot support promotional claims that DELTA achieves equivalent or better image quality; additional testing is needed for such claims. A radiologist and physicist should determine appropriate dose for each diagnostic task, only clinicians or dosimetrists should reduce dose, and DELTA was not thoroughly tested in pediatric patients. Low-dose lung cancer screening must follow an approved and published screening program.
Clinical takeaway. Clinical role: uCT 780 produces whole-body cross-sectional CT images, including head, neck, cardiac, and vascular imaging, supports protocol-governed low-dose lung cancer screening and dual-energy material visualization, and uses DELTA deep-learning reconstruction for adult head, chest, abdomen, cardiac, and vascular applications.
Evidence takeaway. Evidence from the reviewed source record: FDA-reviewed manufacturer evidence includes phantom testing and a 60-subject, two-reader clinical image-quality program with separated training, validation, and test data. The reported acceptance criteria were met, but FDA explicitly limits promotional interpretation and the evidence does not establish patient outcomes.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
uCT 780 produces whole-body cross-sectional CT images, including head, neck, cardiac, and vascular imaging, supports protocol-governed low-dose lung cancer screening and dual-energy material visualization, and uses DELTA deep-learning reconstruction for adult head, chest, abdomen, cardiac, and vascular applications.
Exact FDA submission
Checked 2026-09-19
Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.
Acquires and reconstructs CT examinations, applies DELTA at one of five noise-reduction levels, and supports dual-energy analysis by combining low- and high-energy acquisitions of the same anatomy to visualize material or chemical information and multiple-energy images.
CT projection data acquired on uCT 780; uWS-CT-Dual Energy Analysis accepts United Imaging CT images of the same anatomy acquired at different tube voltages and currents.
Exact FDA submission
Checked 2026-09-19
Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Cross-sectional CT images reconstructed with FBP or DELTA and dual-energy material, chemical, and multiple-energy visualizations for qualified-user review.
Exact FDA submission
Checked 2026-09-19
Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Professional healthcare facilities performing diagnostic CT, cardiac and vascular CT, dual-energy analysis, and protocol-governed lung cancer screening.
A consultation with a radiologist and a physicist should be made to determine the appropriate dose to obtain diagnostic image quality for the particular clinical task; clinicians or dosimetrists should only be allowed to reduce patient dose in clinical practice.
Exact FDA submission
Checked 2026-09-19
This replaces the broader current clinician and imaging-staff label with the packet's direct dose-management user conditions.
The FDA summary states that the submitted clinical study alone cannot support promotional claims that DELTA achieves equivalent or better image quality; additional testing is needed for such claims. A radiologist and physicist should determine appropriate dose for each diagnostic task, only clinicians or dosimetrists should reduce dose, and DELTA was not thoroughly tested in pediatric patients. Low-dose lung cancer screening must follow an approved and published screening program.
Exact FDA submission
Checked 2026-09-19
Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
FDA-reviewed manufacturer evidence includes phantom testing and a 60-subject, two-reader clinical image-quality program with separated training, validation, and test data. The reported acceptance criteria were met, but FDA explicitly limits promotional interpretation and the evidence does not establish patient outcomes.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA-reviewed manufacturer evidence includes phantom testing and a 60-subject, two-reader clinical image-quality program with separated training, validation, and test data. The reported acceptance criteria were met, but FDA explicitly limits promotional interpretation and the evidence does not establish patient outcomes.
DesignManufacturer-sponsored image-quality study with two U.S. board-certified radiologists using five-point ratings for noise, structure fidelity, and overall image quality
Population60 subjects total: 20 validation cases with five each from abdomen, chest, head, and cardiac examinations, plus 40 test cases with ten per body part across different dose levels
Scopeexact submission
Tested versionDELTA on uCT 780 cleared in K241079
Samplen=60
IndependenceSponsor or vendor study
K241079
Training data were excluded from validation and test sets. FDA reports that criteria were met but explicitly states that this study alone cannot support promotional equivalence or superiority claims.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
FDA recall Z-0220-2026 affects uCT 780 systems. A third-party outer cover could become trapped between the patient table and gantry and interfere with table movement. FDA lists the recall as open and classified.
FDA source
Exact FDA submission
Checked 2026-09-04
Each published event was manually matched to the exact FDA submission and affected product or version; a recall does not establish an AI-algorithm defect or current site exposure unless the event states that scope.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: CT projection data acquired on uCT 780; uWS-CT-Dual Energy Analysis accepts United Imaging CT images of the same anatomy acquired at different tube voltages and currents.
Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: DELTA is deployed within the uCT 780 acquisition and image-processing software. The uWS dual-energy application consumes compatible United Imaging CT image sets acquired at two energy settings for the same anatomy.
Scope: Exact FDA submission. Confirm DICOM services, workstation topology, PACS routing, series pairing, quantitative-map handling, licensing, and downstream compatibility for the installed release.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: On-premises uCT 780 CT scanner with embedded DELTA reconstruction and a compatible uWS workstation environment for dual-energy analysis.
Scope: Exact FDA submission.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Cross-sectional CT images reconstructed with FBP or DELTA and dual-energy material, chemical, and multiple-energy visualizations for qualified-user review.
Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Cross-sectional CT images reconstructed with FBP or DELTA and dual-energy material, chemical, and multiple-energy visualizations for qualified-user review.
Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
DELTA is deployed within the uCT 780 acquisition and image-processing software. The uWS dual-energy application consumes compatible United Imaging CT image sets acquired at two energy settings for the same anatomy.
Exact FDA submission
Checked 2026-09-02
Confirm DICOM services, workstation topology, PACS routing, series pairing, quantitative-map handling, licensing, and downstream compatibility for the installed release.
United Imaging Healthcare's cybersecurity page lists a secure development lifecycle and controls: firewall, encrypted connections, OS hardening, antivirus, patches, authentication, audit log, disk and transmission encryption. Company-level, not release-specific.
Vendor-wide
Checked 2026-10-26
Vendor statement, not an attestation; exact-release scope is not established.
DELTA deep-learning reconstruction is embedded in uCT 780 acquisition and processing software for adult head, chest, abdomen, cardiac, and vascular CT and provides five selectable noise-reduction levels.
exact submission · checked 2026-09-02
Validate each protocol, dose target, reconstruction level, artifact pattern, and fallback with radiologist and physicist oversight before routine use.
uWS-CT-Dual Energy Analysis combines compatible low- and high-energy United Imaging CT image sets from the same anatomy to provide material, chemical, and multiple-energy visualizations.
The FDA summary directs sites to consult a radiologist and physicist for task-specific dose selection and limits dose reduction decisions to clinicians or dosimetrists.
exact submission · checked 2026-09-02
Include protocol approval, change control, pediatric restrictions, audit logging, and periodic image-quality review in implementation governance.
United Imaging's current uCT 780 family page presents DELTA reconstruction and spectral and perfusion options, but commercial specifications and options may span configurations or software releases.
product family · checked 2026-09-02
Map every quoted feature, hardware option, interface, service level, and price to the exact installed configuration.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
The packet explicitly identifies uCT 780 as a computed tomography x-ray system; the current dossier modality is null. Controlled directory display reconciled from exact FDA wording: Computed tomography x-ray system. -> CT/CTA.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-04Last searched
25Fields reviewed
10Source classes checked
1Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate record. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. 1 FDA recall candidate was manually reviewed: 1 published and 0 rejected as a neighboring or otherwise inapplicable version. Native FDA recall identifiers produced 1 postmarket candidate record; 1 has been reviewed (1 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, fda device recall, vendor product page, fda decision summary packet, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-10-27 - Exact FDA submission
No public price or quote for the exact K241079 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission
Bounded web search on 2026-10-26 (query: "United Imaging uCT 780 reimbursement"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. This records what was found, not that none exists.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-10-27 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-10-27 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
uCT ATLAS Astound and uCT ATLAS are whole-body CT systems for head, body, cardiac, and vascular imaging, with dual-energy analysis options and protocol-governed low-dose lung-screening use within approved programs.
TrueFidelity deep-learning CT reconstruction produces selectable-strength images for supported head, whole-body, cardiac, and vascular applications on the Discovery CT750 HD family.
Philips Incisive CT provides head, whole-body, cardiac, and vascular CT imaging for patients of all ages and can support qualified low-dose lung screening under labeled programs and protocols.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.